{"filings":[{"id":103124,"accession_number":"0001683168-26-001883","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CNBX Pharmaceuticals issues $45K promissory note to 3i L.P. for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Non-convertible note principal $45,000, due July 1, 2026, with 5% simple interest.","Proceeds used for immediate working capital needs.","Holder may exchange 120% of outstanding balance for equity in a future financing at the lowest price.","Payments include a 20% premium; note may be prepaid on two days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171729,"accession_number":"0001683168-25-000583","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CNBX Pharmaceuticals enters convertible note with $55K initial, up to $850K, 35% discount conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issue Date Jan 23, 2025; maturity Oct 30, 2025; 10% interest, 9% OID, default interest 22%.","Conversion price at 65% of market price (35% discount), exercisable from day 180.","Company may prepay at 110%-130% of face during first 180 days; later subject to holder agreement.","Company must register all shares; holder prohibited from short-selling during term.","Institutional investor 1800 Diagonal Lending LLC provided $55,000, with potential up to $850,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241599,"accession_number":"0001683168-24-001610","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CNBX Pharmaceuticals replaces independent auditor with no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Replaced Weinstein International CPA with Elkana Amitai, CPA effective March 18, 2024.","Auditor change covers fiscal year ended August 31, 2023 and subsequent periods.","No disagreements or reportable events occurred with former auditor during prior fiscal years.","Former accountant's letter attached as Exhibit 16.1; Board approved change on March 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314632,"accession_number":"0001683168-23-000628","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors of CNBX Pharmaceuticals resign effective Jan 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Inbar Maymon Pomeranchik resigned as director; no disagreement with management.","Gil Feiler resigned as director; no disagreement with management.","Resignations occurred on January 31, 2023; no replacements announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333062,"accession_number":"0001683168-22-008672","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Shaul Yemal resigns from CNBX Pharmaceuticals board effective Dec 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shaul Yemal resigned as Director and Board Member on December 25, 2022.","Resignation was not due to any dispute with the company.","No replacement named; board vacancy remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350507,"accession_number":"0001683168-22-005100","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CNBX appoints Dr. Sanja Goldberg as CTO, replacing Dr. Eyal Ballan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Eyal Ballan resigned as CTO and employment ended effective July 20, 2022.","Dr. Sanja Goldberg appointed as new CTO on July 24, 2022.","Goldberg previously held senior researcher roles at Sheba Medical Center's Cancer Research Lab.","She held executive positions at Compugen and TaGeza Biopharma (VP R&D).","Goldberg earned a Ph.D. in Cell Biology from Erasmus MC, Rotterdam in 2009."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367670,"accession_number":"0001683168-22-003584","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"CNBX Pharma effects 1:120 reverse split and cuts authorized preferred to 5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of 1:120 effective May 12, 2022; par value unchanged.","Authorized preferred shares reduced from 100,000,000 to 5,000,000.","Common stock now trades on OTCQB under new symbol CNBXD; new CUSIP 13764M209.","The reverse split was effected by filing a Certificate of Change with Nevada Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387024,"accession_number":"0001683168-22-001999","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Cannabics Pharmaceuticals changes name to CNBX Pharmaceuticals, ticker unchanged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Name change effective March 28, 2022; stock continues trading on OTCQB under symbol CNBX.","Name change reflects transformation to molecule-based drug development for colorectal cancer treatment.","Company preparing Phase I/II clinical validation study for proprietary RCC-33 drug candidate.","Stockholders need not exchange certificates; rights unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387026,"accession_number":"0001683168-22-001701","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2022-03-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cannabics defaults on $1.375M note, obtains forbearance; issues $280K demand note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Forbearance with institutional investor on $1.375M Senior Secured Note due Dec 21, 2021; forbearance through May 7, 2022.","Issued $280K demand promissory note ($240K net after $40K OID) for general working capital.","Demand note payable after earlier of May 16, 2022 or next securities offering; late charge 15% p.a.","Future securities offering proceeds must first repay demand note, then the February Note.","Company acknowledges defaults; waives defenses and holder waives registration rights during forbearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387025,"accession_number":"0001683168-22-001084","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cannabics Pharmaceuticals enters forbearance on $1.375M defaulted note, forbearance until March 7, 2022","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company defaulted on $1,375,000 Senior Secured Convertible Promissory Note due December 21, 2021.","Investor agrees to forbear from enforcing remedies through March 7, 2022, subject to earlier termination.","Investor waives certain defaults and registration rights during the forbearance period.","Company acknowledges no defenses, offsets, or counterclaims regarding the note and its obligations.","Forbearance terminates automatically on March 7, 2022 or upon a Forbearance Default (5 business days cure)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404937,"accession_number":"0001683168-21-005846","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cannabics appoints Shaul Yemal to Board as independent director and Audit Committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to five members; Shaul Yemal appointed as independent director and Audit Committee member.","Yemal brings transnational finance experience, including roles at Israeli Ministry of Finance and Ministry of Energy.","Previously CEO of ICL Santiago, Senior VP at ISAL Amlat VC Fund, and catalyst for Oridion Medical's IPO on Swiss exchange.","No arrangements or understandings with any other person; no related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423966,"accession_number":"0001683168-21-004239","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cannabics Pharmaceuticals appoints Gabriel Yariv as Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gabriel Yariv appointed as Executive Chairman effective September 3, 2021.","Yariv brings over 20 years experience in medical industry; co-founded BreathID (now Medtronic) and SimuTec.","Yariv will continue as Director and Chief Operational Executive while serving as Executive Chair.","Appointment made by unanimous board resolution on September 3, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423965,"accession_number":"0001683168-21-003010","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2021-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cannabics Pharmaceuticals appoints Dr. Gil Feiler as Independent Board Member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gil Feiler appointed as Independent Board Member effective July 15, 2021.","Feiler brings 25+ years executive experience; director of Bank of Georgia, former board member of First International Bank of Israel.","Feiler also heads company's Advisory Board; holds BA, MA, and PhD from Tel Aviv University.","Appointment made by Board resolution; no other changes to board or management disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423964,"accession_number":"0001683168-21-002832","cik":1343009,"company_name":"CNBX Pharmaceuticals Inc.","ticker":"CNBX","form_type":"8-K","filed_at":"2021-07-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dr. Inbar Maymon Pomeranchik appointed as independent board member of Cannabics Pharmaceuticals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Inbar Maymon-Pomeranchik, 43, appointed to board effective July 1, 2021.","Holds a PhD in molecular biology from Hebrew University, postdoc from Weizmann Institute, with 20 years exec experience in biotech and global medical cannabis.","Currently serves as founder & CEO of AgChimedes Group, founder of BioDiligence, Executive Director of Ananda Developments, Director of NRGene, and Advisory Board member of Avida Global.","Appointment was unanimously approved by the Board of Directors on July 1, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202252.05,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}